临床医学工程2024，Vol.31Issue(3)：293-294,2.DOI:10.3969/j.issn.1674-4659.2024.03.0293
贝伐珠单抗联合化疗方案治疗非小细胞肺癌的临床研究
Clinical Study of Bevacizumab Combined with Chemotherapy Regimen in the Treatment of Non-Small Cell Lung Cancer
范海艳 1高青笛2
作者信息
- 1. 商丘市第四人民医院药剂科,河南商丘 476000
- 2. 商丘市第四人民医院肿瘤内科,河南商丘 476000
- 折叠
摘要
Abstract
Objective To explore the clinical effect of bevacizumab combined with chemotherapy regimen in the treatment of non-small cell lung cancer(NSCLC).Methods 66 NSCLC patients admitted to our hospital from June 2018 to June 2022 were randomly divided into routine group and combined group,with 33 cases in each group.The routine group was treated with chemotherapy regimen,and the combined group was treated with bevacizumab combined with chemotherapy regimen.The treatment effect,serum indicator level and quality of life of the two groups were compared.Results The total effective rate of treatment in the combined group was 72.73％,higher than 48.48％in the routine group(P＜0.05).After treatment,the serum CEA,CA125 and CYFRA21-1 levels of the combined group were lower than those in the routine group(P＜0.05).After treatment,the FACT-L score of the combined group was higher than that of the routine group(P＜0.05).Conclusions Bevacizumab combined with chemotherapy regimen in the treatment of NSCLC patients can significantly improve the clinical efficacy,reduce the serum CEA,CA125 and CYFRA21-1 levels,and improve the quality of life.关键词
贝伐珠单抗/化疗方案/非小细胞肺癌/治疗效果/血清指标Key words
Bevacizumab/Chemotherapy regimen/Non-small cell lung cancer/Treatment effect/Serum indicator分类
医药卫生引用本文复制引用
范海艳,高青笛..贝伐珠单抗联合化疗方案治疗非小细胞肺癌的临床研究[J].临床医学工程,2024,31(3):293-294,2.
